{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T07:55:11Z","timestamp":1780905311369,"version":"3.54.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.biopha.2011.04.007","type":"journal-article","created":{"date-parts":[[2011,6,20]],"date-time":"2011-06-20T06:01:38Z","timestamp":1308549698000},"page":"648-654","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Enhanced anti-angiogenesis and anti-tumor activity of endostatin by chemical modification with polyethylene glycol and low molecular weight heparin"],"prefix":"10.1016","volume":"66","author":[{"given":"Haining","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenglin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jichao","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoying","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengshan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2011.04.007_bib0005","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jnci\/82.1.4","article-title":"What is the evidence that tumors are angiogenesis dependent?","volume":"82","author":"Folkman","year":"1989","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.biopha.2011.04.007_bib0010","first-page":"6180","article-title":"Suppression of solid tumor growth by immuno neutralizing monoclonal antibody against human basic fibroblast growth factor","volume":"51","author":"Hori","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2011.04.007_bib0015","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/362841a0","article-title":"Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumor growth in vivo","volume":"362","author":"Kim","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2011.04.007_bib0020","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/367576a0","article-title":"Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant","volume":"367","author":"Millauer","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2011.04.007_bib0025","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0092-8674(94)90200-3","article-title":"Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma","volume":"79","author":"O\u2019Reilly","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2011.04.007_bib0030","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0092-8674(00)81848-6","article-title":"Endostatin: an endogenous inhibitor of angiognesis and tumor growth","volume":"88","author":"O\u2019Reilly","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2011.04.007_bib0035","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1146\/annurev.med.49.1.407","article-title":"Angiogenesis and tumor metastasis","volume":"49","author":"Zetter","year":"1998","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.biopha.2011.04.007_bib0040","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/37126","article-title":"Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance","volume":"390","author":"Boehm","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2011.04.007_bib0045","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1471-2121-6-38","article-title":"The response of VEGF-stimulated endothelial cells to angiostatic molecules is substrate-dependent","volume":"6","author":"Addison","year":"2005","journal-title":"BMC Cell Biol"},{"key":"10.1016\/j.biopha.2011.04.007_bib0050","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1096\/fj.04-2134rev","article-title":"Physiological role of collagen XVIII and endostatin","volume":"19","author":"Marneros","year":"2005","journal-title":"FASEB J"},{"key":"10.1016\/j.biopha.2011.04.007_bib0055","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.3748\/wjg.v10.i22.3361","article-title":"Effects of endostatin on expression of vascular endothelial growth factor and its receptors and neovascularization in colonic carcinoma implanted in nude mice","volume":"10","author":"Jia","year":"2004","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.biopha.2011.04.007_bib0060","first-page":"23","article-title":"Results of phase III trial of rh-endostatin (YH-16) in advanced non-small cell lung cancer (NSCLC) patients","author":"Sun","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.biopha.2011.04.007_bib0065","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.yexcr.2005.11.015","article-title":"Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action","volume":"312","author":"Folkman","year":"2006","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.biopha.2011.04.007_bib0070","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1200\/JCO.2002.11.061","article-title":"Phase I study of recombinant human endostatin in patients with advanced solid tumors","volume":"20","author":"Herbst","year":"2002","journal-title":"J Clin Onco"},{"key":"10.1016\/j.biopha.2011.04.007_bib0075","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.drup.2005.03.001","article-title":"Endostatin: the logic of antiangiogenic therapy","volume":"8","author":"Abdollahi","year":"2005","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.biopha.2011.04.007_bib0080","doi-asserted-by":"crossref","first-page":"38118","DOI":"10.1074\/jbc.M405155200","article-title":"Prolonging the action of protein and peptide drugs by a novel approach of reversible polyethylene glycol modification","volume":"279","author":"Tsubery","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.biopha.2011.04.007_bib0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-3659(01)00215-2","article-title":"Targeting of superoxide dismutase and catalase to vascular endothelium","volume":"71","author":"Muzykantov","year":"2001","journal-title":"J Control Release"},{"key":"10.1016\/j.biopha.2011.04.007_bib0090","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/jb\/mvn060","article-title":"Characterization and secondary structure analysis of endostatin covalently modified by polyethylene glycol and low molecular weight heparin","volume":"144","author":"Tan","year":"2008","journal-title":"J Biochem"},{"key":"10.1016\/j.biopha.2011.04.007_bib0095","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1006\/abio.1997.2405","article-title":"Comparison of results of various methods used to determine the extent of modification methoxy polyethylene glycol modified bovine cupri-zine superoxide dismutase","volume":"254","author":"Bullock","year":"1997","journal-title":"Anal Biochem"},{"key":"10.1016\/j.biopha.2011.04.007_bib0100","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1016\/S0021-9258(17)40291-2","article-title":"Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol","volume":"252","author":"Abuchowski","year":"1977","journal-title":"J Biol Chem"},{"key":"10.1016\/j.biopha.2011.04.007_bib0105","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.3748\/wjg.v10.i10.1409","article-title":"Effects of endostatin-vascular endothelial growth inhibitor chimeric recombinant adenoviruses on antiangiogenesis","volume":"10","author":"Pan","year":"2004","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.biopha.2011.04.007_bib0110","first-page":"21","article-title":"In vivo assessment of epichlorohydrin effects: the chorioallantoic membrane model","volume":"12","author":"Girolamo","year":"2006","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.biopha.2011.04.007_bib0115","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11373-007-9153-7","article-title":"Inhibition of corneal neovascularization with endostatin delivered by adeno-associated viral (AAV) vector in a mouse corneal injury model","volume":"14","author":"Lai","year":"2007","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.biopha.2011.04.007_bib0120","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00055735-200108000-00002","article-title":"Corneal neovascularization","volume":"12","author":"Chang","year":"2001","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.biopha.2011.04.007_bib0125","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0002-9440(10)61697-5","article-title":"Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin","volume":"159","author":"Mori","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1016\/j.biopha.2011.04.007_bib0130","first-page":"842","article-title":"Targeting of interferon to choroidal neovascularization by use of dextran and metal coordination","volume":"43","author":"Yasukawa","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.biopha.2011.04.007_bib0135","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1248\/bpb.31.454","article-title":"Antitumor activity of pisosterol in mice bearing with S180 tumor","volume":"31","author":"Carvalho Montenegro","year":"2008","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.biopha.2011.04.007_bib0140","doi-asserted-by":"crossref","first-page":"9012","DOI":"10.1158\/0008-5472.CAN-04-2172","article-title":"The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization","volume":"64","author":"Olsson","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2011.04.007_bib0145","first-page":"113","article-title":"Preparation of a polyethylene glycol: superoxide dismutase adduct, and an examination of its blood circulation life and anti-inflammatory activity","volume":"29","author":"Pyatak","year":"1980","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"10.1016\/j.biopha.2011.04.007_bib0150","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1600-0463.2006.apm_235.x","article-title":"Low-molecular-weight heparins and angiogenesis","volume":"114","author":"Norrby","year":"2006","journal-title":"APMIS"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332211000461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332211000461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:51:04Z","timestamp":1760093464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332211000461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0753332211000461"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2011.04.007","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced anti-angiogenesis and anti-tumor activity of endostatin by chemical modification with polyethylene glycol and low molecular weight heparin","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2011.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}